Scholarlink

<p>The phase 3 ENESTPath study investigated treatment-free remission (TFR) rates in patients with chronic Philadelphia chromosome-positive (Ph+) and/or <i>BCR::ABL1</i><sup>+</sup> chronic myeloid leukemia who had not achieved deep molecular response (DMR) after &gt;2 years of imatinib treatment and were switched to nilotinib 300 mg twice daily (BID). After 24 months of treatment, patients with a stable DMR were randomized to either enter the TFR phase (Arm 1) or continue nilotinib consolidation for an additional 12 months and then enter the TFR phase if in stable DMR (Arm 2). The primary endpoint was the proportion of patients who remained in TFR (≥MR<sup>4.0</sup> [<i>BCR::ABL1</i><sup>IS</sup> ≤ 0.01%]) without molecular relapse at the end of 12 months. Of the 620 patients enrolled, 239 (38.5%) achieved stable MR<sup>4.0</sup> and were randomized to Arm 1 (<i>n</i> = 120) or Arm 2 (<i>n</i> = 119). In the TFR phase, MR<sup>4.0</sup> rates at 12 months (Arm 1: 31.9%, Arm 2: 37.5%; <i>p</i> = 0.383) and 24 months (Arm 1: 29.4%, Arm 2: 30.8%) revealed no differences in TFR success between 2 and 3 years of nilotinib. Irrespective of the consolidation duration, switching to nilotinib 300 mg BID provided the opportunity to achieve TFR if patients were unable to reach stable DMR with first-line imatinib.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results

  • 期刊论文

  • 发表日期：

    2026年1月19日

查看全文
  • Delphine Rea,
  • Slawomira Kyrcz-Krzemien,
  • Paolo Sportoletti,
  • Jiří Mayer,
  • Arpad Illes,
  • Anna Angona Figueras,
  • Alexander Kiani,
  • Aude Charbonnier,
  • Theodoros Marinakis,
  • Leif Stenke,
  • Juan Luis Steegmann,
  • Giuseppe Saglio,
  • Andrzej Hellmann,
  • Dietger Niederwieser,
  • Peter Schuld,
  • Gianantonio Rosti

摘要

The phase 3 ENESTPath study investigated treatment-free remission (TFR) rates in patients with chronic Philadelphia chromosome-positive (Ph+) and/or BCR::ABL1+ chronic myeloid leukemia who had not achieved deep molecular response (DMR) after >2 years of imatinib treatment and were switched to nilotinib 300 mg twice daily (BID). After 24 months of treatment, patients with a stable DMR were randomized to either enter the TFR phase (Arm 1) or continue nilotinib consolidation for an additional 12 months and then enter the TFR phase if in stable DMR (Arm 2). The primary endpoint was the proportion of patients who remained in TFR (≥MR4.0 [BCR::ABL1IS ≤ 0.01%]) without molecular relapse at the end of 12 months. Of the 620 patients enrolled, 239 (38.5%) achieved stable MR4.0 and were randomized to Arm 1 (n = 120) or Arm 2 (n = 119). In the TFR phase, MR4.0 rates at 12 months (Arm 1: 31.9%, Arm 2: 37.5%; p = 0.383) and 24 months (Arm 1: 29.4%, Arm 2: 30.8%) revealed no differences in TFR success between 2 and 3 years of nilotinib. Irrespective of the consolidation duration, switching to nilotinib 300 mg BID provided the opportunity to achieve TFR if patients were unable to reach stable DMR with first-line imatinib.